Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by G. Clot
Gene Mutations and Copy Number Alterations (Cna) Predict for Early Failure in Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) Treated With R-Chop
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients With Diffuse Large B-Cell (DLBCL) and High-Grade Lymphoma Treated With Immunochemotherapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Diffuse Large B-Cell Lymphoma Presenting With Gastrocolic Fistula and Successfully Treated With R-Chop Chemotherapy
Tenri Medical Bulletin
Multiplex Polymerase Chain Reaction-Based Prognostic Models in Diffuse Large B-Cell Lymphoma Patients Treated With R-Chop
British Journal of Haematology
Hematology
Blood Lymphocyte-To-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated With R-Chop
PLoS ONE
Multidisciplinary
Increased MYC Gene Copy Number Correlates With Increased mRNA Levels in Diffuse Large B-Cell Lymphoma
Haematologica
Hematology
Identification of Gene Modules Associated With Survival of Diffuse Large B-Cell Lymphoma Treated With CHOP-based Chemotherapy
Pharmacogenomics Journal
Molecular Medicine
Genetics
Pharmacology
Tumor Necrosis as a Prognostic Factor of Diffuse Large B-Cell Lymphoma Treated With R-Chop Therapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Accept: A Phase Ib/Ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop) for Patients With Diffuse Large B-Cell Lymphoma (Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
MELK Serves as a Potent Independent Biomarker to Predict Survival of Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-Chop Regimen
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology